Indoramin in the treatment of hypertension. A mini-review and update.
The origins, preclinical development and clinical pharmacology of a new antihypertensive agent, indoramin (Baratol; Wyeth), are briefly reviewed. Indoramin is a competitive postsynaptic alpha-adrenoceptor antagonist with a myocardial membrane-stabilizing component of action. These features are believed to be responsible for its antihypertensive efficacy. They may also explain the absence of problems common to older alpha-blockers such as reflex tachycardia and postural hypotension. Clinical evaluation of a new agent such as indoramin in the management of hypertension is discussed in terms of efficacy, dosage regimen, tolerance, adverse effects, interactions, withdrawal syndrome, and long-term influence on the complications of high blood pressure.
D000818:Animals; D004285:Dogs; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006168:Guinea Pigs; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use*; D007217:Indoramin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D007211:Indoles; D007217:Indoramin